UK signs deals for 90 million virus vaccine doses

The vaccines are being researched by an alliance between the pharmaceutical companies BioNtech and Pfizer as well as the firm Valneva.

The new deal is on top of 100 million doses of the Oxford University vaccine being developed by AstraZeneca.

However, it is still uncertain which of the experimental vaccines may work.

A vaccine is widely seen as the best chance of getting our lives back to normal.

Research is taking place at an unprecedented scale – the world became aware of coronavirus at the beginning of the year, but already more than 20 vaccines are in clinical trials.

Some can provoke an immune response, but none has yet been proven to protect against infection.

The UK government has now secured access to vaccines that use three completely different approaches:

100m doses of the Oxford vaccine made from a genetically engineered virus.

30 million doses of the BioNtech/Pfizer vaccine, which injects part of the coronavirus’ genetic code.

60 million doses of the Valneva, which uses an inactive version of the coronavirus.

Using different styles of vaccine maximises the chance that one of them will work.

Kate Bingham, the chair of the government’s Vaccine Taskforce, said: “The fact that we have so many promising candidates already shows the unprecedented pace at which we are moving.

“But I urge against being complacent or over optimistic.

“The fact remains we may never get a vaccine and if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms.”